专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4158176A Spatial filter system as an optical relay line 失效
标题翻译：空间滤波器系统作为光中继线
公开(公告)号：US4158176A
公开(公告)日：1979-06-12
申请号：US830972
申请日：1977-09-06
申请人： John T. Hunt , Paul A. Renard
发明人： John T. Hunt , Paul A. Renard
IPC分类号： H01S3/00 , H01S3/02
CPC分类号： H01S3/005
摘要： A system consisting of a set of spatial filters that are used to optically relay a laser beam from one position to a downstream position with minimal nonlinear phase distortion and beam intensity variation. The use of the device will result in a reduction of deleterious beam self-focusing and produce a significant increase in neutron yield from the implosion of targets caused by their irradiation with multi-beam glass laser systems.
摘要翻译：由一组空间滤波器组成的系统，其用于以最小的非线性相位失真和光束强度变化将激光束从一个位置光学中继到下游位置。该装置的使用将导致有害光束自聚焦的减少，并且由于其由多光束玻璃激光系统照射引起的目标内爆产生显着增加的中子产量。

2. 发明授权

US4574916A Step to safety 失效
标题翻译：踏踏实实
公开(公告)号：US4574916A
公开(公告)日：1986-03-11
申请号：US748162
申请日：1985-06-24
申请人： John T. Hunt , George Spector
发明人： John T. Hunt , George Spector
IPC分类号： E06C9/00 , E06C5/34
CPC分类号： E06C7/081 , E06C9/00
摘要： A safety step fire escape is provided and consists of a plurality of steps mounted in a vertical spaced relationship to an outside wall of a building adjacent windows of the building. The last step is elevated high enough from ground level so that a person can only climb down the fire escape. A descent cable extends through the steps to guide the person down the fire escape. A signaling device is operable by movement of the descent cable from its normal position.
摘要翻译：提供安全步骤防火逃生，并且由与建筑物的建筑物的窗户的建筑物的外壁的垂直隔开的关系安装的多个台阶构成。最后一步从地面升高到足够高的地方，以至于一个人只能爬起火来逃跑。下降的电缆延伸穿过台阶，以引导人员逃离逃生。信号装置可通过下降电缆从其正常位置的移动来操作。

3. 发明授权

US06521759B2 Aminothiazole inhibitors of cyclin dependent kinases 有权
标题翻译：细胞周期蛋白依赖性激酶的氨基噻唑抑制剂
公开(公告)号：US06521759B2
公开(公告)日：2003-02-18
申请号：US09839751
申请日：2001-04-20
申请人： Kyoung S. Kim , S. David Kimball , Zhen-wei Cai , David B. Rawlins , Raj N. Misra , Michael A. Poss , Kevin R. Webster , John T. Hunt , Wen-Ching Han
发明人： Kyoung S. Kim , S. David Kimball , Zhen-wei Cai , David B. Rawlins , Raj N. Misra , Michael A. Poss , Kevin R. Webster , John T. Hunt , Wen-Ching Han
IPC分类号： C07D41712
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D417/12 , C07D417/14
摘要： The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.
摘要翻译：本发明描述了式I的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，m和n如说明书中所定义。式I的化合物是蛋白激酶抑制剂，可用于治疗增殖性疾病，例如癌症，炎症和关节炎。它们也可用于治疗阿尔茨海默病，化学疗法诱发的脱发和心血管疾病。

4. 发明授权

US06458783B1 Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase 失效
标题翻译：法尼基蛋白转移酶的非咪唑苯并二氮类抑制剂
公开(公告)号：US06458783B1
公开(公告)日：2002-10-01
申请号：US09556740
申请日：2000-04-21
申请人： Charles Z. Ding , John T. Hunt , Katerina Leftheris , Rajeev S. Bhide
发明人： Charles Z. Ding , John T. Hunt , Katerina Leftheris , Rajeev S. Bhide
IPC分类号： A61K31675
CPC分类号： C07D401/06 , C07D243/14 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D409/06 , C07D409/12 , C07D413/06
摘要： Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
摘要翻译：对参与ras癌基因表达的酶的法呢基转移酶的抑制是由formulastheir对映异构体，非对映异构体及其药学上可接受的盐，前药和溶剂化物的化合物进行的。

5. 发明授权

US06455523B1 Inhibitors of farnesyl protein transferase 失效
公开(公告)号：US06455523B1
公开(公告)日：2002-09-24
申请号：US09374210
申请日：1999-08-13
申请人： Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
发明人： Charles Z. Ding , Soong-Hoon Kim , John T. Hunt , Toomas Mitt , Rajeev Bhide , Katerina Leftheris
IPC分类号： A61K3155
CPC分类号： C07D243/14 , C07D401/14 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/00 , C07D487/04 , C07D495/04
摘要： Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression. In formulas I-IV and throughout their specification, the above symbols are defined as follows: m, n, r, s and t are 0 or 1; p is 0, 1 or 2; V, W and X are selected from the group consisting of oxygen, hydrogen, R1, R2 or R3; Z and Y are selected from the group consisting of CHR9, SO2, SO3, CO, CO2, O, NR10, So2NR11, CONR12, or Z may be absent; R6, R7, R9, R10, R11, R12 R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R24, R25, R26, R27, R28, R29, R30, R31, R32,R33, R34, R35, R36, R37, and R38 are selected from the group consisting of hydrogen, lower alkyl, substituted alkyl, aryl or substituted aryl; R4, R5 are selected from the group consisting of hydrogen, halo, nitro, cyano and U-R23; U is selected from the group consisting of sulfur, oxygen, NR24, CO, SO, SO2, CO2, NR25CO2, NR26CONR27, NR28SO2, NR29SO2NR30, SO2NR31, NR32CO, CONR33, PO2R34 and PO3R35 or U is absent; R1, R2, and R3 are selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, cyano, carboxy, carbamyl (e.g. CONH2) or substituted carbamyl further selected from CONH alkyl, CONH aryl, CONH aralkyl or cases where there are two substituents on the nitrogen selected from alkyl, aryl or aralkyl; R8 and R23 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo; Any two of R1, R2, and R3 can be joined to form a cycloalkyl group; R, S and T are selected from the group consisting of CH2, CO and CH(CH2)pQ wherein Q is NR36R37, OR38, or CN; and A, B, C and D are carbon, oxygen, sulfur or nitrogen. with the provisos that 1. When m is zero then V and W are not both oxygen or 2 W and X together can be oxygen only if Z is either absent, O, NR10, in formulas I and II, and V and X together can be oxygen only if Y is O, NR10, in formulas III and IV or 3. R23 may be hydrogen except when U is SO, SO2, NR25CO2 or NR28SO2, or 4. R8 may be hydrogen except when Z is SO2, CO2, or

6. 发明授权

US6040321A Aminothiazole inhibitors of cyclin dependent kinases 有权
标题翻译：细胞周期蛋白依赖性激酶的氨基噻唑抑制剂
公开(公告)号：US6040321A
公开(公告)日：2000-03-21
申请号：US176239
申请日：1998-10-21
申请人： Kyoung S. Kim , S. David Kimball , Zhen-wei Cai , David B. Rawlins , Raj N. Misra , Michael A. Poss , Kevin R. Webster , John T. Hunt , Wen-Ching Han
发明人： Kyoung S. Kim , S. David Kimball , Zhen-wei Cai , David B. Rawlins , Raj N. Misra , Michael A. Poss , Kevin R. Webster , John T. Hunt , Wen-Ching Han
IPC分类号： C07D277/20 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/506 , A61P1/04 , A61P9/00 , A61P9/10 , A61P9/14 , A61P17/02 , A61P17/06 , A61P19/02 , A61P21/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/10 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/06 , A61P43/00 , C07D263/00 , C07D277/00 , C07D277/42 , C07D277/44 , C07D277/54 , C07D417/12 , C07D417/14 , A61K31/425
CPC分类号： C07D417/14 , C07D417/12
摘要： Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings:R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl;R.sub.3 is aryl or heteroarylR.sub.4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; orCO-alkyl,CONH-alkyl,COO-alkyl,SO.sub.2 -alkyl,C(NCN)NH-alkyl,C(NNO.sub.2)NH-alkyl,C(NH)NH-alkyl,C(NH)NHCO-alkyl,C(NOR.sub.6)NH-alkyl,R.sub.5 is hydrogen or alkyl;R.sub.6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;m is an integer of 0 to 2; andn is an integer of 1 to 3.The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.
摘要翻译：式的化合物及其药学上可接受的盐。如式I所用，在整个说明书中，符号具有以下含义：R 1和R 2独立地为氢，氟或烷基; R 3是芳基或杂芳基R 4是氢，烷基，环烷基，芳基，环烷基烷基，芳基烷基，杂芳基，杂芳基烷基，杂环烷基，杂环烷基烷基; 或（C 1 -C 10）烷基，C 1 -C 6烷基，CO 2 - 烷基，SO 2 - 烷基，C（NCN）NH-烷基，C （NOR6）NH-烷基，R5是氢或烷基; R 6是氢，烷基，环烷基，芳基，环烷基烷基，芳基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基; m为0〜2的整数; 并且n是1至3的整数。式I化合物是蛋白激酶抑制剂，可用于治疗和预防增殖性疾病，例如癌症，炎症和关节炎。它们也可用于治疗神经变性疾病如阿尔茨海默病，心血管疾病，病毒性疾病和真菌性疾病。

7. 发明授权

US07244733B2 Pyrrolotriazine inhibitors of kinases 有权
标题翻译：吡咯并三嗪激酶抑制剂
公开(公告)号：US07244733B2
公开(公告)日：2007-07-17
申请号：US11345845
申请日：2006-02-02
申请人： John T. Hunt , Rajeev S. Bhide , Robert Michael Borzilleri , Ligang Qian
发明人： John T. Hunt , Rajeev S. Bhide , Robert Michael Borzilleri , Ligang Qian
IPC分类号： A61K31/53 , A61P35/00 , A61P19/02 , C07D487/04
CPC分类号： C07D519/00 , C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译：本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2，FGFR-1，PDGFR，HER-1，HER-2的酪氨酸激酶活性，从而使其成为抗癌剂。式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。

8. 发明授权

US06982265B1 Pyrrolotriazine inhibitors of kinases 有权
标题翻译：吡咯并三嗪激酶抑制剂
公开(公告)号：US06982265B1
公开(公告)日：2006-01-03
申请号：US09573829
申请日：2000-05-18
申请人： John T. Hunt , Rajeev S. Bhide , Robert Michael Borzilleri , Ligang Qian
发明人： John T. Hunt , Rajeev S. Bhide , Robert Michael Borzilleri , Ligang Qian
IPC分类号： C07D487/04 , A61K31/153 , A61P35/00 , A61P27/02 , A61P29/00
CPC分类号： C07D519/00 , C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译：本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2，FGFR-1，PDGFR，HER-1，HER-2的酪氨酸激酶活性，从而使其成为抗癌剂。式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。

9. 发明授权

US06900208B2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders 有权
标题翻译：吡咯并哒嗪化合物及其用于治疗增殖性疾病的方法
公开(公告)号：US06900208B2
公开(公告)日：2005-05-31
申请号：US10396197
申请日：2003-03-25
申请人： Mark Salvati , Stephanie A. Barbosa , Zhong Chen , John T. Hunt
发明人： Mark Salvati , Stephanie A. Barbosa , Zhong Chen , John T. Hunt
IPC分类号： A61K31/5025 , A61K45/06 , C07D487/04 , C07D487/14 , A61P5/28 , A61P35/00
CPC分类号： C07D487/04 , A61K31/5025 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： Disclosed are pyrrolopyridazine compounds of the formula, wherein the substituents are defined herein, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
摘要翻译：公开了下式的吡咯并哒嗪化合物，其中取代基在本文中定义，制备此类化合物的方法及其用于治疗增殖性，炎症性和其它障碍的用途。

10. 发明授权

US6107320A Phenyl sulfonamide endothelin antagonists 失效
标题翻译：苯磺酰胺内皮素拮抗剂
公开(公告)号：US6107320A
公开(公告)日：2000-08-22
申请号：US584767
申请日：1996-01-11
申请人： Natesan Murugesan , John T. Hunt
发明人： Natesan Murugesan , John T. Hunt
IPC分类号： A61K31/42 , A61K31/422 , A61K31/423 , C07D261/12 , C07D261/16 , C07D261/18 , C07D261/20
CPC分类号： C07D261/16 , C07D261/18 , C07D261/20
摘要： Compounds of the formula ##STR1## inhibit the activity of endothelin. The symbols are defined as follows: R.sup.1, R.sup.2 and R.sup.3 are each independently(a) hydrogen, except that R.sup.1 is other than hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ;(c) halo;(d) hydroxyl;(e) cyano;(f) nitro;(g) --C(O)H or --C(O)R.sup.6 ;(h) --CO.sub.2 H or --CO.sub.2 R.sup.6 ;(i) --SH, --S(O).sub.n R.sup.6, --S(O).sub.m --OH, --S(O).sub.m --OR.sup.6, --O--S(O).sub.m --R.sup.6, --O--S(O).sub.m OH or --O--S(O).sub.m --OR.sup.6 ;(j) --Z.sup.4 --NR.sup.7 R.sup.8 ; or(k) --Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10 ;and the remaining symbols are as defined in the specification.
摘要翻译：该化合物可抑制内皮素的活性。符号定义如下：R1，R2和R3各自独立地为（a）氢，除了R1不是氢; （b）烷基，烯基，炔基，烷氧基，环烷基，环烷基烷基，环烯基，环烯基烷基，芳基，芳氧基，芳烷基或芳烷氧基，其中任一个可以被Z1，Z2和Z3取代; （c）卤素; （d）羟基; （e）氰基; （f）硝基; （g）-C（O）H或-C（O）R 6; （h）-CO 2 H或-CO 2 R 6; （ⅰ）-SH，-S（O）nR 6，-S（O）m -OH，-S（O）m -OR 6，-OS（O）m -R 6，-OS（O）mOH或-OS O）m-OR6; （j）-Z4-NR7R8; 或（k）-Z4-N（R11）-Z5-NR9R10; 其余符号如说明书中所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式